FDA Clearance Tracker · P240012
AeroPace® System
Last checked: Nov 20, 2026Latest source record: Dec 4, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Dec 4, 2024
Approved
Time to decision
240 days
Received Apr 8, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P240012
- Device name
- AeroPace® System
- Applicant
- Lungpacer Medical USA, Inc.
- Applicant location
- Exton, PA
- Received
- Apr 8, 2024
- Decided
- Dec 4, 2024
- Decision
- Approved
- Supplements
- 8 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for AeroPace® System. The AeroPace System is indicated to improve weaning success increase weaning, reduce ventilator days, and reduce reintubation - in patients ages 18 years or older on mechanical ventilation >= 96 hours and who have not weaned.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SDL (Transvenous temporary phrenic nerve stimulator).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for Lungpacer Medical USA, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.